Riskpilot← Back to searchSign inGet full accessVaccinova AB
ABActiveOrg 5569830002Bielkegatan 2 CGeneral medical practice activities · NACE 8621Est. 201449 employees
Revenue 2024
SEK 89,2M
+29% vs 2023
EBITDA margin
5.2%
-36% vs 2023
Equity ratio
39.7%
Financial strength
Net profit 2024
SEK 3,4M
-38% vs 2023
| Revenue | SEK 89,2M | +29% |
| EBITDA | SEK 4,7M | -36% |
| Net profit | SEK 3,4M | -38% |
| Total assets | SEK 14,1M | +2% |
| Equity | SEK 5,6M | -22% |
| Employees | 49 | — |
Legal name
Vaccinova AB
Org number
5569830002
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
15 september 2014
Share capital
SEK 50 000
Employees
49 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget ska bedriva vaccinationsverksamhet, hälso- och sjukvård samt marknadsföring av nämnda områden och därmed förenlig verksamhet.
Address
Bielkegatan 2 C
Email
ulf@vaccinova.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 12 039 | 27 127 | 37 751 | 69 166 | 89 206 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 1 897 | 746 | −408 | 7 323 | 4 651 |
| Depreciation & amort. | −0 | −96 | −158 | −249 | −328 |
| EBIT | 1 897 | 650 | −566 | 7 074 | 4 323 |
| Net financials | −72 | −12 | −24 | 23 | 62 |
| Profit before tax | 1 859 | 639 | 36 | 6 996 | 4 373 |
| Tax | −405 | −152 | −35 | −1 468 | −931 |
| Net profit | 1 454 | 487 | 1 | 5 528 | 3 442 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 4 152 | 4 878 | 5 838 | 13 852 | 14 134 |
| Equity | 1 504 | 1 641 | 1 642 | 7 170 | 5 612 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1 942 | 2 533 | 4 116 | 6 501 | 8 328 |
| Total debt | 1 942 | 2 533 | 4 116 | 6 501 | 8 328 |
EBITDA margin
5.2%
This company
15.8%
Market median
-67% vs market
20202024
Equity ratio
39.7%
This company
38.2%
Market median
+4% vs market
20202024
Return on equity
61.3%
This company
18.4%
Market median
+233% vs market
20202024
Net profit margin
3.9%
This company
8.1%
Market median
-52% vs market
20202024
Asset turnover
6.31×
This company
1.12×
Market median
+463% vs market
20202024
Debt / equity
1.52×
This company
0.62×
Market median
-145% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
PF Chief Auditor | Chief Auditor | 2020 |
UL Chief Executive Officer | Chief Executive Officer | 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
| Former (2) | ||
| Deputy Board Member | 2020 – 2021 | |
| Board of Directors | 2023 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Vaccinova AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Fredrik Önnerth | Chief Auditor | 0 companies |
| Ulf Lennart Andersson | Chief Executive Officer | 0 companies |
| Eva Marie Kristofersson | Deputy Board Member | 0 companies |
| Erik Martin Fagerlund | Board of Directors | 0 companies |
| Ludvig Anders Toan Salomonsson | Deputy Board Member | 0 companies |